Contineum Therapeutics (CTNM) Enterprise Value (2023 - 2025)
Contineum Therapeutics (CTNM) has 3 years of Enterprise Value data on record, last reported at -$182.4 million in Q3 2025.
- For Q3 2025, Enterprise Value rose 14.73% year-over-year to -$182.4 million; the TTM value through Sep 2025 reached -$182.4 million, up 14.73%, while the annual FY2024 figure was -$204.8 million, 63.56% down from the prior year.
- Enterprise Value reached -$182.4 million in Q3 2025 per CTNM's latest filing, down from -$175.5 million in the prior quarter.
- Across five years, Enterprise Value topped out at -$117.9 million in Q1 2024 and bottomed at -$218.7 million in Q2 2024.
- Average Enterprise Value over 3 years is -$178.6 million, with a median of -$186.6 million recorded in 2025.
- Peak YoY movement for Enterprise Value: crashed 63.56% in 2024, then increased 19.74% in 2025.
- A 3-year view of Enterprise Value shows it stood at -$125.2 million in 2023, then crashed by 63.56% to -$204.8 million in 2024, then rose by 10.92% to -$182.4 million in 2025.
- Per Business Quant database, its latest 3 readings for Enterprise Value were -$182.4 million in Q3 2025, -$175.5 million in Q2 2025, and -$190.7 million in Q1 2025.